Myosin modulators: Emerging approaches for the treatment of cardiomyopathies and heart failure
Name:
148557.1-20220224104908-covere ...
Size:
1.586Mb
Format:
PDF
Description:
Final Published Version
Affiliation
Department of Biomedical Engineering, University of ArizonaIssue Date
2022
Metadata
Show full item recordCitation
Day, S. M., Tardiff, J. C., & Michael Ostap, E. (2022). Myosin modulators: Emerging approaches for the treatment of cardiomyopathies and heart failure. Journal of Clinical Investigation.Rights
Copyright © 2022, Day et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Myosin modulators are a novel class of pharmaceutical agents that are being developed to treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to target cardiac myosins directly to modulate contractility and cardiac power output to alleviate symptoms that lead to heart failure and arrhythmias, without altering calcium signaling. In this Review, we discuss two classes of drugs that have been developed to either activate (omecamtiv mecarbil) or inhibit (mavacamten) cardiac contractility by binding to β-cardiac myosin (MYH7). We discuss progress in understanding the mechanisms by which the drugs alter myosin mechanochemistry, and we provide an appraisal of the results from clinical trials of these drugs, with consideration for the importance of disease heterogeneity and genetic etiology for predicting treatment benefit. © 2022 American Society for Clinical Investigation. All rights reserved.Note
Open access articleISSN
0021-9738PubMed ID
35229734Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1172/JCI148557
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2022, Day et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Related articles
- Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction.
- Authors: Auguin D, Robert-Paganin J, Réty S, Kikuti C, David A, Theumer G, Schmidt AW, Knölker HJ, Houdusse A
- Issue date: 2024 Jun 7
- Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
- Authors: Mack M, Frishman WH
- Issue date: 2024 Jul-Aug 01
- Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
- Authors: Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA
- Issue date: 2016
- Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.
- Authors: Nanasi P, Komaromi I, Gaburjakova M, Almassy J
- Issue date: 2018
- Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
- Authors: Psotka MA, Teerlink JR
- Issue date: 2017